A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Clinical Study to Investigate the Efficacy and Safety of 50 mg Daridorexant in Adult and Elderly Chinese Patients With Insomnia Disorder.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daridorexant (Primary)
Indications Insomnia
Focus Registrational; Therapeutic Use
Sponsors Jiangsu Simcere Pharmaceutical

Most Recent Events

30 Oct 2024 Status changed from active, no longer recruiting to completed.
25 Jul 2024 According to Idorsia Pharmaceuticals media release, positive phase 3 by Simcere in Greater China NDA submitted.
16 Jul 2024 According to a Simcere Pharmaceutical Group media release, company announced that the new drug application for Quviviq has been accepted by the National Medical Products Administration.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight